• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2型奥密克戎变异株基因组序列及其与大流行结束相关的流行病学关联:计算机模拟分析

SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis.

作者信息

Kumar Ashutosh, Asghar Adil, Singh Himanshu N, Faiq Muneeb A, Kumar Sujeet, Narayan Ravi K, Kumar Gopichand, Dwivedi Prakhar, Sahni Chetan, Jha Rakesh K, Kulandhasamy Maheswari, Prasoon Pranav, Sesham Kishore, Kant Kamla, Pandey Sada N

机构信息

Department of Anatomy All India Institute of Medical Sciences-Patna Patna India.

Etiologically Elusive Disorders Research Network New Delhi India.

出版信息

JMIR Bioinform Biotechnol. 2023 Jan 10;4:e42700. doi: 10.2196/42700. eCollection 2023.

DOI:10.2196/42700
PMID:36688013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9843602/
Abstract

BACKGROUND

Emergence of the new SARS-CoV-2 variant B.1.1.529 worried health policy makers worldwide due to a large number of mutations in its genomic sequence, especially in the spike protein region. The World Health Organization (WHO) designated this variant as a global variant of concern (VOC), which was named "Omicron." Following Omicron's emergence, a surge of new COVID-19 cases was reported globally, primarily in South Africa.

OBJECTIVE

The aim of this study was to understand whether Omicron had an epidemiological advantage over existing variants.

METHODS

We performed an in silico analysis of the complete genomic sequences of Omicron available on the Global Initiative on Sharing Avian Influenza Data (GISAID) database to analyze the functional impact of the mutations present in this variant on virus-host interactions in terms of viral transmissibility, virulence/lethality, and immune escape. In addition, we performed a correlation analysis of the relative proportion of the genomic sequences of specific SARS-CoV-2 variants (in the period from October 1 to November 29, 2021) with matched epidemiological data (new COVID-19 cases and deaths) from South Africa.

RESULTS

Compared with the current list of global VOCs/variants of interest (VOIs), as per the WHO, Omicron bears more sequence variation, specifically in the spike protein and host receptor-binding motif (RBM). Omicron showed the closest nucleotide and protein sequence homology with the Alpha variant for the complete sequence and the RBM. The mutations were found to be primarily condensed in the spike region (n=28-48) of the virus. Further mutational analysis showed enrichment for the mutations decreasing binding affinity to angiotensin-converting enzyme 2 receptor and receptor-binding domain protein expression, and for increasing the propensity of immune escape. An inverse correlation of Omicron with the Delta variant was noted (r=-0.99, <.001; 95% CI -0.99 to -0.97) in the sequences reported from South Africa postemergence of the new variant, subsequently showing a decrease. There was a steep rise in new COVID-19 cases in parallel with the increase in the proportion of Omicron isolates since the report of the first case (74%-100%). By contrast, the incidence of new deaths did not increase (r=-0.04, >.05; 95% CI -0.52 to 0.58).

CONCLUSIONS

In silico analysis of viral genomic sequences suggests that the Omicron variant has more remarkable immune-escape ability than existing VOCs/VOIs, including Delta, but reduced virulence/lethality than other reported variants. The higher power for immune escape for Omicron was a likely reason for the resurgence in COVID-19 cases and its rapid rise as the globally dominant strain. Being more infectious but less lethal than the existing variants, Omicron could have plausibly led to widespread unnoticed new, repeated, and vaccine breakthrough infections, raising the population-level immunity barrier against the emergence of new lethal variants. The Omicron variant could have thus paved the way for the end of the pandemic.

摘要

背景

新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变种B.1.1.529的出现令全球卫生政策制定者感到担忧,因为其基因组序列存在大量突变,尤其是在刺突蛋白区域。世界卫生组织(WHO)将该变种指定为全球关注变种(VOC),命名为“奥密克戎”。奥密克戎出现后,全球报告的新型冠状病毒肺炎(COVID-19)病例激增,主要集中在南非。

目的

本研究旨在了解奥密克戎相对于现有变种是否具有流行病学优势。

方法

我们对全球共享禽流感数据倡议组织(GISAID)数据库中可获取的奥密克戎完整基因组序列进行了计算机模拟分析,以从病毒传播性、毒力/致死率和免疫逃逸方面分析该变种中存在的突变对病毒-宿主相互作用的功能影响。此外,我们对特定SARS-CoV-2变种的基因组序列相对比例(2021年10月1日至11月29日期间)与来自南非的匹配流行病学数据(新增COVID-19病例和死亡病例)进行了相关性分析。

结果

根据WHO的定义,与当前全球VOC/关注变种(VOI)列表相比,奥密克戎具有更多的序列变异,特别是在刺突蛋白和宿主受体结合基序(RBM)方面。奥密克戎在完整序列和RBM方面与阿尔法变种显示出最接近的核苷酸和蛋白质序列同源性。发现这些突变主要集中在病毒的刺突区域(n = 28 - 48)。进一步的突变分析表明,突变富集导致与血管紧张素转换酶2受体的结合亲和力降低以及受体结合域蛋白表达减少,同时免疫逃逸倾向增加。在新变种出现后南非报告的序列中,奥密克戎与德尔塔变种呈负相关(r = -0.99,<.001;95%置信区间 -0.99至 -0.97),随后呈下降趋势。自首例病例报告以来,随着奥密克戎毒株分离株比例的增加,新增COVID-19病例急剧上升(从74%升至100%)。相比之下,新增死亡病例的发生率没有增加(r = -0.04,>.05;95%置信区间 -0.52至0.58)。

结论

对病毒基因组序列的计算机模拟分析表明,奥密克戎变种比包括德尔塔在内的现有VOC/VOI具有更显著的免疫逃逸能力,但毒力/致死率低于其他已报告变种。奥密克戎更高的免疫逃逸能力可能是COVID-19病例再度流行并迅速成为全球优势毒株的原因。奥密克戎比现有变种更具传染性但致死率更低,可能导致了广泛的未被注意到的新的、反复的和疫苗突破性感染,提高了人群对新的致死变种出现的免疫屏障。因此,奥密克戎变种可能为大流行的结束铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/9e493e57a958/bioinform_v4i1e42700_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/c85c8d60b3de/bioinform_v4i1e42700_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/0d183e255d5f/bioinform_v4i1e42700_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/841333a84562/bioinform_v4i1e42700_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/9e493e57a958/bioinform_v4i1e42700_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/c85c8d60b3de/bioinform_v4i1e42700_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/0d183e255d5f/bioinform_v4i1e42700_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/841333a84562/bioinform_v4i1e42700_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2479/11213267/9e493e57a958/bioinform_v4i1e42700_fig4.jpg

相似文献

1
SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis.严重急性呼吸综合征冠状病毒2型奥密克戎变异株基因组序列及其与大流行结束相关的流行病学关联:计算机模拟分析
JMIR Bioinform Biotechnol. 2023 Jan 10;4:e42700. doi: 10.2196/42700. eCollection 2023.
2
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新变种及针对冠状病毒(COVID-19)的新型疗法
3
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.关注的新冠病毒变异株的生物学功能及临床意义
Front Med (Lausanne). 2022 May 20;9:849217. doi: 10.3389/fmed.2022.849217. eCollection 2022.
4
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.关于关注的 SARS-CoV-2 奥密克戎变异株及其特殊突变特征的最新信息。
Microbiol Spectr. 2022 Apr 27;10(2):e0273221. doi: 10.1128/spectrum.02732-21. Epub 2022 Mar 30.
5
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.印度的新冠疫情动态、严重急性呼吸综合征冠状病毒2(SARS-CoV-2)德尔塔变异株及其对疫苗接种的影响
medRxiv. 2021 Nov 22:2021.06.21.21259268. doi: 10.1101/2021.06.21.21259268.
6
In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.基于计算机的全基因组分析揭示了 SARS-CoV-2 奥密克戎结构变化对宿主免疫逃逸和抗病毒治疗的影响及其进化。
Viruses. 2022 Nov 6;14(11):2461. doi: 10.3390/v14112461.
7
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?奥密克戎变异株(B.1.1.529)及其亚谱系:在 SARS-CoV-2 重组变异株出现之际,我们目前了解多少?
Biomed Pharmacother. 2022 Oct;154:113522. doi: 10.1016/j.biopha.2022.113522. Epub 2022 Aug 15.
8
Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.运用计算模型研究了 5 种突变对 ACE2 受体结构的影响,及其与 SARS-CoV-2 一些新兴变异株感染性和毒力的相关性,结果提示了结合亲和力失调的机制。
Chem Biol Interact. 2022 Dec 1;368:110244. doi: 10.1016/j.cbi.2022.110244. Epub 2022 Nov 3.
9
A Preliminary Genomic Analysis of the Omicron Variants of SARS-CoV-2 in Central India During the third wave of the COVID-19 Pandemic.新冠病毒奥密克戎变异株在印度中部第三次新冠疫情大流行期间的初步基因组分析。
Arch Med Res. 2022 Sep;53(6):574-584. doi: 10.1016/j.arcmed.2022.08.006. Epub 2022 Aug 23.
10
SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.奥密克戎变异株(B.1.1.529)引起的 SARS-CoV-2 疫苗突破性感染(VBI)及其对结构和功能影响的后果。
Cell Signal. 2023 Sep;109:110798. doi: 10.1016/j.cellsig.2023.110798. Epub 2023 Jul 7.

引用本文的文献

1
Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens.暴露于 SARS-CoV-2 或接种过疫苗的个体中的抗体反应针对多种 CoV-2 抗原的保守表位。
Int J Mol Sci. 2024 Sep 11;25(18):9814. doi: 10.3390/ijms25189814.
2
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2.主蛋白酶和类木瓜蛋白酶作为新型冠状病毒SARS-CoV-2药物治疗的潜在靶点。
RSC Adv. 2023 Dec 6;13(50):35500-35524. doi: 10.1039/d3ra06479d. eCollection 2023 Nov 30.
3
Investigation of the individual genetic evolution of SARS-CoV-2 in a small cluster during the rapid spread of the BF.5 lineage in Tokyo, Japan.

本文引用的文献

1
A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy.意大利米兰地区奥密克戎毒株与早期新冠病毒变体疾病严重程度的比较
Front Epidemiol. 2022 Jun 28;2:891162. doi: 10.3389/fepid.2022.891162. eCollection 2022.
2
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants.阿尔法至奥密克戎:主要 SARS-CoV-2 变异株的疾病严重程度和临床结局。
J Infect Dis. 2023 Feb 1;227(3):344-352. doi: 10.1093/infdis/jiac411.
3
A Bioinformatics Tool for Predicting Future COVID-19 Waves Based on a Retrospective Analysis of the Second Wave in India: Model Development Study.
日本东京BF.5谱系快速传播期间一个小聚集群中新型冠状病毒(SARS-CoV-2)个体基因进化的调查。
Front Microbiol. 2023 Sep 6;14:1229234. doi: 10.3389/fmicb.2023.1229234. eCollection 2023.
4
A Bioinformatics Tool for Predicting Future COVID-19 Waves Based on a Retrospective Analysis of the Second Wave in India: Model Development Study.一种基于对印度第二波新冠疫情回顾性分析预测未来新冠疫情波次的生物信息学工具:模型开发研究
JMIR Bioinform Biotechnol. 2022 Sep 22;3(1):e36860. doi: 10.2196/36860. eCollection 2022 Jan-Dec.
一种基于对印度第二波新冠疫情回顾性分析预测未来新冠疫情波次的生物信息学工具:模型开发研究
JMIR Bioinform Biotechnol. 2022 Sep 22;3(1):e36860. doi: 10.2196/36860. eCollection 2022 Jan-Dec.
4
Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study.奥密克戎(B.1.1.529)与德尔塔(B.1.617.2)相关的 COVID-19 死亡风险比较:回顾性队列研究。
BMJ. 2022 Aug 2;378:e070695. doi: 10.1136/bmj-2022-070695.
5
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.恢复期血清和疫苗血清及单克隆抗体对 SARS-CoV-2 奥密克戎亚变种 BA.1 和 BA.2 的中和作用有限。
EBioMedicine. 2022 Aug;82:104158. doi: 10.1016/j.ebiom.2022.104158. Epub 2022 Jul 11.
6
Variant-driven early warning via unsupervised machine learning analysis of spike protein mutations for COVID-19.基于 Spike 蛋白突变的无监督机器学习分析的变异驱动早期预警用于 COVID-19。
Sci Rep. 2022 Jun 3;12(1):9275. doi: 10.1038/s41598-022-12442-8.
7
Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates.新冠大流行期间 Delta 和奥密克戎变异株的叠加流行:动态面板数据估计。
JMIR Public Health Surveill. 2022 Jun 3;8(6):e37377. doi: 10.2196/37377.
8
Is Omicron the end of pandemic or start of a new innings?奥密克戎是疫情的终结还是新征程的开始?
Travel Med Infect Dis. 2022 Jul-Aug;48:102332. doi: 10.1016/j.tmaid.2022.102332. Epub 2022 Apr 23.
9
Estimating disease severity of Omicron and Delta SARS-CoV-2 infections.估算奥密克戎和德尔塔 SARS-CoV-2 感染的疾病严重程度。
Nat Rev Immunol. 2022 May;22(5):267-269. doi: 10.1038/s41577-022-00720-5.
10
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.